Status:

COMPLETED

Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

Lead Sponsor:

Mologen AG

Conditions:

Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at lea...

Eligibility Criteria

Inclusion

  • Male and female patients with extensive disease SCLC ≥ 18 years of age receiving first line treatment;
  • Histology of SCLC or mixed histology of SCLC if SCLC histology is at least 80%;
  • Completion of 4 cycles of first-line therapy with a platinum-based regimen and no other prior chemotherapy;
  • Documented evidence of tumor response as assessed by investigators after the first 2 cycles of platinum-based chemotherapy followed by a confirmed PR or CR at the end of fourth cycle by CT or MRI scan;
  • Brain metastases are allowed only after cranial irradiation, if not requiring continuous treatment with steroids or anticonvulsants;
  • ECOG performance status 0 or 1;
  • Adequate organ function with total bilirubin, lactate dehydrogenase \[LDH\], alkaline phosphatase \[AP\], gamma glutamyltransferase \[GGT\], albumin, creatinine, urea, electrolytes, and coagulation parameters ≤ 1.5 × upper limit of normal (ULN), and with aspartate aminotransferase \[AST\] and ALT ≤ 2.5 × ULN in the absence of liver metastases or ≤ 5.0 × ULN in the presence of liver metastases;
  • Adequate hematological parameters: absolute neutrophil count ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; leukocyte count ≥ 3.0 × 109/L; lymphocytes ≥ 1.0 × 109/L; hemoglobin ≥ 9.0 g/dL or 5.59 mmol/L;
  • Patients with reproductive potential agree to use effective contraceptive measures throughout the study;
  • Negative pregnancy test in women of childbearing potential;
  • Signed informed consent form (ICF).

Exclusion

    Key Trial Info

    Start Date :

    March 1 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 5 2017

    Estimated Enrollment :

    103 Patients enrolled

    Trial Details

    Trial ID

    NCT02200081

    Start Date

    March 1 2014

    End Date

    October 5 2017

    Last Update

    November 15 2018

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Medizinische Universitaet Innsbruck

    Innsbruck, Austria, 6020

    2

    Universitair Ziekenhuis Gent

    Ghent, Belgium, 9000

    3

    Thoraxklinik Heidelberg gGmbH

    Heidelberg, Baden-Wurttemberg, Germany, 69126

    4

    Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain, 28040